|
gptkbp:instanceOf
|
antineoplastic agent
|
|
gptkbp:administeredBy
|
radiotherapy
|
|
gptkbp:approvalYear
|
1999
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
L01AX03
|
|
gptkbp:bioavailability
|
100%
|
|
gptkbp:brand
|
gptkb:Temodal
gptkb:Temodar
|
|
gptkbp:CASNumber
|
85622-93-1
|
|
gptkbp:category
|
antineoplastic agent
imidazotetrazine derivative
|
|
gptkbp:chemicalFormula
|
C6H6N6O2
|
|
gptkbp:contraindication
|
severe myelosuppression
hypersensitivity to temozolomide
|
|
gptkbp:developedBy
|
gptkb:Schering-Plough
|
|
gptkbp:discoveredBy
|
gptkb:Malcolm_Stevens
|
|
gptkbp:eliminationHalfLife
|
1.8 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:firstSynthesized
|
1987
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
temozolomide
|
|
gptkbp:interactsWith
|
gptkb:phenytoin
gptkb:valproic_acid
gptkb:carbamazepine
live vaccines
|
|
gptkbp:KEGGID
|
D06053
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
DNA methylation
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
194.15 g/mol
|
|
gptkbp:origin
|
gptkb:United_Kingdom
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:prodrugOf
|
MTIC (5-(3-methyltriazen-1-yl)imidazole-4-carboxamide)
|
|
gptkbp:proteinBinding
|
10-20%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL606
5394
DB00853
|
|
gptkbp:riskFactor
|
immunosuppression
teratogenicity
secondary malignancies
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
vomiting
fatigue
myelosuppression
|
|
gptkbp:solubility
|
3.3 mg/mL
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:UNII
|
JEP0YGT94R
|
|
gptkbp:usedFor
|
gptkb:glioblastoma_multiforme
gptkb:anaplastic_astrocytoma
|
|
gptkbp:bfsParent
|
gptkb:multidrug_resistance-associated_protein_1
gptkb:Stupp_protocol
gptkb:glioblastoma_multiforme
|
|
gptkbp:bfsLayer
|
6
|